Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
Anova Enterprises has launched the AnovaOS SaaS platform, a new AI-based patient matching solution for clinical trials.
Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.
Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...
Eli Lilly’s oral GLP-1RA, orforglipron, has offered significant weight maintenance benefits during a Phase III study in obesity. Image credit: ChrisStock82 via Shutterstock.com. Eli Lilly’s oral ...
Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...
Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...
The Clinicaltrials.gov listing states the termination is due to “business reasons” Image credit: Avishek Das / SOPA Images / LightRocket via Getty Images. Sarepta Therapeutics has terminated a Phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback